Engineered MSCs for Allogeneic Islet Transplantation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current islet transplantation methods for type 1 diabetes require systemic immunosuppression, which can be toxic to islets and has deleterious side effects for patients, making it essential to develop alternative strategies that minimize or eliminate systemic immunosuppression.

Innovation Solution

Recombinant mesenchymal stromal cells (MSCs) engineered to overexpress immunomodulatory proteins such as PD-L1, CTLA4-Ig, CD47, CD39, CD73, IL-10, and IDO1 are used in conjunction with islet cells to create a mixed cell population that promotes local immunotolerance at the graft site, reducing the need for systemic immunosuppression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic immunosuppression is used to prevent allograft rejection, then graft acceptance is improved, but toxicity to islets and deleterious side effects increase

Engineering Contradiction:

Improvegraft acceptanceVSAvoidtoxicity to islets and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces accessory cells as intermediary elements that mediate between the allogeneic islet graft and the host immune system. These accessory cells express immunomodulatory proteins (PD-L1, CTLA4-Ig, CD39, CD73, IDO1, IL-10) to locally regulate immune responses, replacing the need for systemic immunosuppressive drugs and thereby eliminating their toxic side effects while maintaining graft acceptance.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent implements local immunomodulation by equipping accessory cells with specific immunomodulatory proteins that act locally at the graft site. This localized approach allows immune regulation to occur precisely where needed (at the islet graft interface) without requiring systemic administration of immunosuppressive agents, thus avoiding their harmful systemic effects while maintaining effective graft protection.

Inventive Principle:

Principle #3Local quality

2Reliability

If accessory cells expressing multiple immunomodulatory proteins are used, then local immunotolerance is improved, but device complexity increases

Engineering Contradiction:

Improvelocal immunotoleranceVSAvoidcell engineering complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs accessory cells that simultaneously express multiple immunomodulatory proteins (PD-L1, CTLA4-Ig, CD39, CD73, IDO1, IL-10), making these cells multi-functional. Each protein targets different immune pathways, and their combined expression in a single cell type creates a comprehensive local immunosuppressive environment that addresses multiple aspects of the immune response to the graft, thereby achieving robust local immunotolerance through a unified cellular platform.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250170184A1Engineered immunomodulatory accessory cells improve allogeneic islet transplantation without immunosuppression

Publication Date: 2025.05.29 CORNELL UNIVERSITY

AI summary

Disclosed herein are recombinant mesenchymal stromal cells (e MSCs) that expresses one or more immunomodulatory proteins or polypeptides as well as mixed cell populations that include the eMSCs and one or more cell types distinct of the eMSC, such as islet cells or islets. Also disclosed are implantable cell culture devices that include eMSCs or the mixed cell populations. The eMSCs can be used to improve survival of transplanted cells (such as an allograft), and more particularly to methods of modifying T cell response to an allograft and treating a diabetic subject.